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Abstract
Background Epidermal growth factor receptor inhibitors
(EGFRI) produce various dermatologic side effects in the
majority of patients, and guidelines are crucial for the
prevention and treatment of these untoward events. The
purpose of this panel was to develop evidence-based recom-
mendations for EGFRI-associated dermatologic toxicities.
Methods A multinational, interdisciplinary panel of experts in
supportive care in cancer reviewed pertinent studies using
established criteria in order to develop first-generation recom-
mendations for EGFRI-associated dermatologic toxicities.
Results Prophylactic and reactive recommendations for pap-
ulopustular (acneiform) rash, hair changes, radiation derma-
titis, pruritus, mucositis, xerosis/fissures, and paronychia are
presented, as well as general dermatologic recommendations
when possible.
Conclusion Prevention and management of EGFRI-related
dermatologic toxicities is critical to maintain patients’
health-related quality of life and dose intensity of antineo-
plastic regimens. More rigorous investigation of these
toxicities is warranted to improve preventive and treatment
strategies.
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Background
Overexpression of the epidermal growth factor receptor
(EGFR) is strongly associated with cancer development and
progression of a number of malignancies. EGFR inhibitors
(EGFRI) are targeted agents used for treating lung
(erlotinib), pancreatic (erlotinib in combination with gem-
citabine), breast (lapatinib in combination with capecitabine
or anastrozole), head and neck (cetuximab in combination
with radiotherapy), and colorectal cancers (cetuximab,
panitumumab) [1]. EGFRI may be used as first-line through
third-line treatments, alone or in combination with other
agents in the aforementioned cancers.
Commonly experienced dermatologic side effects in-
clude papulopustular (acneiform) rash, hair changes, radi-
ation dermatitis enhancement, pruritus, mucositis, xerosis/
fissures, and paronychia. Incidences of these side effects are
frequent and range from 36% for mucositis to 80% for
papulopustular (acneiform) rash. Clinical presentation,
incidence, impact on quality of life and cost, effect on
EGFRI dosing, and risk factors for these toxicities have
been described elsewhere [1]. When severe, dermatologic
toxicities may to lead to dose modification or discontinu-
ation by 36% and 72% of health care providers, respec-
tively [2]. Although the side effect profile may be primarily
dermatologic, toxicities result in significant physical and
emotional discomfort, thus it is critical to maximize
supportive measures.
Although most patients receiving EGFRIs experience
these toxicities, few controlled studies have been conducted
to determine the best practices for their management.
Instead, much of the literature contains prevention and
treatment recommendations based on case reports or studies
with small samples sizes and nonrandomized patient
allocation. In addition, available reports are beset with
methodological issues including failure to adequately
describe assessment tools or frequency, lack of validated
tools for the assessment of dermatologic toxicities, and
passive data collection. Given that these agents are
relatively devoid of systemic and hematopoietic toxicities
and have shown benefit in a variety of solid tumors, further
large-scale studies to define best supportive care are
necessary but are unlikely to become available in the
foreseeable future. The purpose of this article is to provide
comprehensive supportive care prevention and treatment
recommendations for EGFRI-induced dermatologic toxic-
ities based on the pertinent literature currently available. In
cases where randomized clinical trials specific to EGFRI
toxicities were not available, trials investigating phenotyp-
ically similar dermatologic conditions were analyzed and
reported.
Methods
Participants
The Multinational Association for Supportive Care in Cancer
(MASCC) Skin Toxicity Study Group assembled an interna-
tional, interdisciplinary group of experts in dermatology,
medical and supportive oncology, health-related quality of
life (HQOL), and pharmacovigilance. Topic review commit-
tees were formed according to expertise to review the
literature and develop guidelines for the following dermato-
logictoxicities:papulopustular(acneiform)rash,hairchanges,
radiation dermatitis, pruritus, mucositis, xerosis/fissures, and
paronychia.
Recommendation development
Each review committee consisted of three members with a
primary reviewer to present the findings of the committee
to the Skin Toxicity Study Group. Literature reviews were
performed via databases such as Ovid MEDLINE (National
Library of Medicine, Bethesda, MD, USA) and EMBASE
(Elsevier B.V. Amsterdam, The Netherlands). Published
literature as of November 2010 was included and each
committee reviewed between 17 and 35 papers to formulate
the recommended guidelines. Randomized clinical trials
were considered the best source, and considerations for
recommendations included Level of Evidence and Grade of
Recommendation (Tables 1 and 2)[ 3]. In the absence of
experimental evidence, pertinent studies and case reports
were presented in conjunction with expert opinion derived
from clinical practice. Recommendations were developed
based on the presented findings and panel consensus. When
available, data were extrapolated from other dermatologic
conditions with similar clinical or pathologic characteristics
(xerosis, alopecia and hirsutism, pruritus, paronychia, and
radiation dermatitis).
Table 1 Levels of evidence [3]
Level I evidence is reserved for meta-analyses of randomized
controlled trials or randomized trials with high power.
Level II evidence includes randomized trials with lower power.
Level III evidence includes nonrandomized trials, such as cohort or
case-controlled series.
Level IV evidence includes descriptive and case studies.
Level V evidence includes case reports and clinical examples.
1080 Support Care Cancer (2011) 19:1079–1095Results and recommendations
Papulopustular (acneiform) rash
During the first weeks to months of EGFRI therapy, a
papulopustular (acneiform) rash is the most clinically
significant dermatologic toxicity. The rash usually develops
in cosmetically sensitive areas, and it affects the majority of
treated patients. Pruritic and tender erythematous papules
and pustules develop in skin (Fig. 1a–c) with a high density
of sebaceous glands (scalp, face, upper chest, and back).
Histological analyses reveal a superficial inflammatory cell
infiltrate surrounding hyperkeratotic or ectatic follicular
infundibula or a florid neutrophilic suppurative folliculitis
with rupture of epithelial lining. The rash is noteworthy for
its impact on psychosocial well-being, related costs,
secondary infections, and effects on dose intensity. As
measured using Skindex-16, an HQOL tool used in
dermatology, greater severity of rash will result in a greater
decrement in HQOL, with emotions being the most
important aspect of people’s lives affected. Pain, burning,
and irritation were common symptoms affecting the
majority of patients [4]. Moreover, a survey of oncology
practitioners demonstrated that 32% of providers discon-
tinued therapy and 76% modified dose due to rash when
severe [5].
Several factors have been associated with an increased risk
ofdeveloping rash: for erlotinib,nonsmokers,peoplewithfair
skin, and older than 70; for cetuximab, male gender and those
younger than 70. Moreover, severe rash is more frequent with
monoclonal antibodies (10–17%) than with low-molecular-
weight tyrosine kinase inhibitors (5–9%). As with other
toxicities, management can be preventive/prophylactic or
treatment/reactive.
Randomized controlled trials for EGFRI rash have been
conducted in the preventive/prophylactic setting, whereas
uncontrolled reports reveal options for reactive treatment.
Table 3 displays the recommendations for the prevention and
treatment of papulopustular (acneiform) rash. Based on the
high frequency of rash in EGFRI-treated patients and the
consistent presentation within the first 2–4 weeks of therapy,
preventive/prophylactic management is recommended unless
there are contraindications based on patient and/or health
care provider factors [6–12]. Hydrocortisone 1% combined
with moisturizer, sunscreen, and doxycycline 100 mg bid for
the first 6 weeks is recommended based on randomized data.
Another study revealed that prophylactic minocycline
100 mg daily is an effective agent in reducing the number
of lesions during the first 8 weeks. Doxycycline appears to
have a more favorable safety profile, especially in patients
with renal dysfunction, whereas minocycline is less photo-
sensitizing, thus preferable in geographic or seasonal
locations with a high UV index.
Reactive use of medium- to high-potency topical cortico-
steroids is recommended based on studies showing in vitro
release of inflammatory chemokines after EGFRI therapy.
Vitamin K3 (menadione) is currently being investigated,
but published reports on vitamin K1 are based on studies
without control groups [13, 14]. Similarly, studies investi-
gating isotretinoin for the treatment of EGFRI-induced rash
have not included control groups, but consistent reports of
isotretinoin at doses lower than those used for acne support
the recommendation of their use when other measures have
failed. Additional support for isotretinoin is provided by
patient reports of improved HQOL, and there is evidence of
clinical response to the EGFRI [1, 15–17]. Although the
rash peaks in weeks 4–6 after EGFRI initiation and
decreases in severity after weeks 6–8, postinflammatory
skin alterations (erythema and hyperpigmentation) are long-
term sequelae that can last for months or years. Therefore,
prophylactic strategies are important, and appropriate
medication (Table 3) should be considered throughout
EGFRI treatment and follow-up in order to minimize these
late effects.
Hair changes
A variety of hair changes have been described in patients
taking EGFRI and include trichomegaly (elongation and
curling of the eyelashes), hypertrichosis often presenting as
facial hirsutism, and scalp hair changes ranging from
brittleness and slowed growth to alopecia. Nonscarring
alopecia occurs after 2–3 months of therapy and may present
as frontal or patchy patterns, with a tendency to progress to
diffuse alopecia with prolonged EGFRI therapy, which may
resolve spontaneously in some patients. Alopecia generally
resolvesafterdiscontinuationoftherapy,thoughhairregrowth
may be of varying quality. No interventions to reduce or
prevent nonscarring alopecia in these patients have been
published in the literature, and recommended interventions
are supportive (education, cosmetic approaches for patient
comfort) and based on studies in androgenetic (male-pattern)
and female alopecia (Table 4).
Minoxidil has been found effective for treating non-
scarring alopecia in the general patient population [18–20].
In two studies, males’ subjective reporting of increased hair
growth was statistically significant for both the 2% and 5%
Table 2 Recommendation grades [3]
Grade A is reserved for level I evidence or consistent findings from
multiple studies of levels II, III, or IV evidence.
Grade B is for levels II, III, or IV evidence with generally consistent
findings.
Grade C is similar to grade B but with inconsistencies.
Grade D implies little or no evidence.
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Fig. 1 a Mild papulopustular
(acneiform) rash, b and c pap-
ulopustular (acneiform) rash, d
and e radiation dermatitis, f and
g mucositis, h fingertip fissure,
and i paronychia
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also were significantly higher in the two treatment groups
[18, 19]. Similar findings were reported in one study with
females randomized to the same two treatment groups
versus placebo group for hair count, although no difference
was found between the groups for subjective reporting of
increased hair changes [20]. Higher incidences of pruritus
and hypertrichosis were reported in the minoxidil 5% group
than in the 2% group [18, 19]. These should be monitored if
minoxidil is prescribed for patients receiving EGFRIs as
these also are possible skin toxicities associated with the
EGFRI therapy.
Scarring alopecia also has been reported in these patients
and is consequent to scalp, facial, and chest lesions that can
lead to permanent hair loss. Prevention and management
strategies, based on expert opinion, aim to reduce inflamma-
tion and scarring for patients receiving EGFRI therapy.
Options include topical hydrocortisone 0.2%, steroid
shampoos, and class 1 steroid lotions [21]. Use of bath oils
or mild shampoo followed by antibiotic spray has been
recently reported [22]. Preventive strategies for reducing
papulopustular (acneiform) rash severity, as described above,
also should be employed to minimize scarring alopecia.
Facial hypertrichosis (hirsutism) and trichomegaly appear
after the first 1–2 months of therapy, and these symptoms do
not wane over time; instead, they tend to persist for the
duration of therapy with EGFRIs. Unwanted or excess facial
hair may be treated with temporary or permanent hair
removal. Trichomegaly is associated with patient discomfort
andtheabnormaleyelashgrowthcanleadtocornealabrasions
andfurther ocularcomplications.Trichomegaly canbetreated
with lash clipping every 2–4 weeks, and referral to an
ophthalmologist is indicated for patients with irritation or
persistent discomfort. Topical eflornithine cream has been
well tolerated and efficacious for the treatment of hirsutism in
open-label trials with the general female population and has
been found to significantly improve HQOL in a randomized
clinical trial [23, 24]. Laser hair removal has been shown to
reduce hair growth in a small sample [25], but eflornithine
plus laser hair removal has been reported to be more
effective than laser hair removal alone in randomized trials
with the general population [26, 27]. Amelioration of
symptoms, patient education, and support are recommended
for patients with hair changes so that EGFRI therapy may
continue.
Radiation dermatitis
The development of some degree of radiation dermatitis is
considered inevitable for the majority of patients receiving
Table 3 Papulopustular (acneiform) rash recommendations
Recommend Not recommended Level of
evidence
Recommendation
grades
Comments
Preventive (weeks 1–6 and 8 of EGFRI initiation)
Topical Hydrocortisone 1% cream
with moisturizer and
sunscreen twice daily
Pimecrolimus
1% cream
II
a C
Tazarotene
0.05% cream
Sunscreen as
single agent
Systemic Minocycline
100 mg daily
Tetracycline
500 mg bid
II
a A Doxycycline is preferred
in patients with renal
impairment. Minocycline
is less photosensitizing.
Doxycycline 100 mg bid
Treatment
Topical Alclometasone
0.05% cream
Vitamin K1 cream IV
a C
Fluocinonide
0.05% cream bid
Clindamycin 1%
Systemic Doxycycline 100 mg bid Acitretin IV
a C Photosensitizing agents
Minocycline 100 mg daily
Isotretinoin at low doses
(20–30 mg/day)
aEGFRI study
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and connective tissue changes that usually develop within
the first few weeks of radiation initiation. Furthermore,
higher incidence of high-grade radiation dermatitis results
from the addition of EGFRIs to radiotherapy [28].
Radiation dermatitis ranges from erythema and dry or wet
desquamation to skin necrosis or ulceration of full thickness
dermis with spontaneous bleeding from the involved site
(Fig. 1d, e).
The establishment of a proper technique to minimize the
dose delivered to the epidermis and a quality assurance
program for radiotherapy planning and delivery is critical
not only in therapeutic terms but also from the perspective
of avoiding unnecessary skin toxicity. A primary step in the
management of radiation dermatitis of any severity is to
establish that the skin reactions are not a result of any
concomitant medication, other than EGFRI. In the case of
more severe skin reactions, correct radiation dose and
distribution should be verified.
Table 5 displays the recommendations for the prevention
and treatment of radiation dermatitis. An important step in
managing and treating radiation dermatitis is to keep the
irradiated area clean and dry, even when ulcerated. Gentle
washing and drying of the skin within the radiation portal
have been shown to reduce the acute radiotherapy-
associated skin reactions in patients receiving radiotherapy
for breast cancer and is now routinely recommended for all
patients receiving radiotherapy [29, 30]. A number of
topical agents can be considered, all of which are
considered high-potency topical corticosteroids (mometa-
sone, methylprednisolone, beclomethasone, and betametha-
sone creams [31, 32].
The recently reported results of Radiation Therapy
Oncology Group trials (99-13) in patients with squamous
cell carcinoma of the head and neck failed to show any
benefit of the systematic use of interventional or prophy-
lactic trolamine emulsion in reducing skin toxicity [33].
Another study showed no significant benefit of pentoxifyl-
line prophylaxis on the development of acute skin reactions
[34]. The potential benefit of oral zinc supplementation in
postponing the development of severe mucositis and
dermatitis and in alleviating the degree of mucositis and
dermatitis in patients receiving radiotherapy for cancers of
the head and neck [35] warrants additional confirmatory
studies.
Where infection is suspected, the treating physician
should use best clinical judgment for management, includ-
ing considering swabbing the affected area for identifica-
tion of the infectious agent. In patients for whom skin
infection is suspected or documented, the neutrophil count
Table 4 Hair changes recommendations
Recommend Not recommended Level of
evidence
Recommendation
grades
Comments
Preventive hair loss
Topical For scarring alopecia, follow
rash recommendations
Preventive interventions for
nonscarring alopecia
VD
Systemic For scarring alopecia, follow
rash recommendations
Preventive interventions for
nonscarring alopecia
VD
Treatment hair loss
Topical Nonscarring I
a/II/III/
IV
b
B/D Consensus
of experts Minoxidil 2%, 5% bid
Scarring
Class 1 steroid lotion,
shampoo, or foam
Antibiotic lotion
Preventive increased hair
Patient education and support IV B Consensus
of experts
Treatment increased hair
Facial
hypertrichosis
Eflornithine Waxing, chemical depilatories IV
b,I I
a B Consensus of
experts Lasers
Eyelash
trichomegaly
Eyelash trimmings regularly IV B
aNon-EGFRI noncancer treatment study
bEGFRI study
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concomitant chemotherapy. Indeed, severe desquamation is
associated with a risk of septicemia. Blood cultures should
also be carried out if additional signs of sepsis and/or fever
are present, particularly if the neutrophil count is low.
Where there is coexistence of radiation dermatitis and
EGFRI-related papulopustular (acneiform) rash within an
irradiated field, management depends on the severity of
radiation dermatitis. Prophylactic therapy directed against
the radiation dermatitis (with high-potency topical cortico-
steroids) and an oral antibiotic (doxycycline or minocy-
cline) for the EGFRI rash should be considered. For mild
radiation dermatitis, it is prudent to follow the published
findings on the management of EGFRI-related papulopust-
ular (acneiform) rash outside irradiated fields [35–37]. For
moderate–severe radiation dermatitis, it is important to
investigate for possible secondary Staphylococcus aureus
infection.
Pruritus
Pruritus occurs in approximately half of all EGFRI-treated
patients, and although it rarely requires dose modifications
or discontinuation of drug therapy, it can have dramatic
impact upon the patient’s HQOL. It is important to note that
the occurrence of pruritus often accompanies papulopustular
(acneiform) rash at onset; hence, it is important to emphasize
thatappropriatetreatmentofunderlyingrashalsocanalleviate
the pruritic symptoms. Because itching can also occur as a
consequence of dry skin, it is important to ensure adequate
measures are provided to prevent dryness (see the “Xerosis
and fissures” section).Currently, the mechanism of action
behind pruritus induced by EGFRIs is not clearly elucidated.
Histamine, which is released by mast cells in persons with
urticaria, is classically associated with pruritus. It is unknown
whether other neurotransmitters or receptors (including
serotonin, opioids, and gamma-aminobutyric acid) explain
the pruritus that is experienced by patients treated with
EGFRIs.
In the literature, no clinical studies are designed to study
specific primary endpoints to evaluate the most optimal
therapy for EGFRI-induced pruritus. Hence, much of the
data originated from case series as well as case reports on
various agent approaches for pruritus relief. However, a
number of clinical management guidelines have provided
insights how EGFRI-induced pruritus should be managed
[38, 39]. Table 6 displays the recommendations for the
treatment of pruritus.
Table 5 Radiation dermatitis recommendations
Recommend Not recommended Level of
evidence
Recommendation
grades
Comments
Preventive
Topical Maintain hygiene, gently clean and
dry skin in the radiation field,
shortly before radiation treatment
Moisturizers, gels, emulsions,
and dressings should not be
applied shortly before RT
IV
a A
Topical High-potency topical steroids Trolamine LED (photons) I
a A
Systemic Pentoxifylline/zinc
supplementation
II
a/V
a B/D Consensus of experts: no
systemic treatment in
the preventive setting
Treatment
Topical Maintain hygiene and gently clean
and dry skin in the radiation field,
even when ulcerated
Hyaluronic acid cream IV A Consensus of experts
Topical Moisturizers/antibacterial
moisturizers
Anti-inflammatory
emulsion (trolamine)
IV
a/V
b B/C Consensus of experts
Topical Drying gels IV
b B Consensus of experts
Antiseptics (chlorhexidine)
Topical Hydrophilic dressings V
b D
Topical Antibiotics when infection is
suspected
IV
a B Consensus of experts
Systemic Antibiotics: doxycycline II
c B Consensus of experts
Others Blood cultures should be carried out
if fever and/or signs of sepsis
I
b A
aNon-EGFRI cancer treatment study
bNon-EGFRI noncancer treatment study
cEGFRI study
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symptom relief to patients with mild to moderate pruritus of
various etiologies. Data in the setting of EGFRI is limited
and conflicting. In one study, two patients were given
loratadine for 14 days; however, patients did not find it
useful and discontinued treatment [22]. Thus, pharmaco-
logic guidance must be sought from trials conducted in
other patient populations.
In another study, a second-generation antihistamine
(loratadine) was shown to be equally effective as hydroxyzine
(a first-generation antihistamine) in patients with chronic
idiopathic urticaria and atopic dermatitis. Moreover, lorata-
dine is not associated with sedative side effects that are
commonly observed with hydroxyzine. One study has
demonstrated that somnolence or sedation was recorded in
5% of loratadine patients and 40% of hydroxyzine patients
after 1 week of drug usage [40]. Another study involving
loratadine and hydroxyzine demonstrated similar results. The
efficacy is similar between treatment groups, but patients
treated with loratadine had significantly less (p<0.01)
sedation and dry mouth compared to patients treated with
hydroxyzine [41]. Hence, nonsedating second-generation
antihistamines are recommended as the first approach for
systemic therapy for pruritus during daytime. Dosing of
antihistamines also should be kept to the minimum to avoid
adverse drug reactions, particularly in the elderly, as these
medications may cause severe anticholinergic reactions. For
p a t i e n t sw h os u f f e rf r o mp r u r i t u sd u r i n gn i g h t t i m e ,f i r s t -
generation antihistamines (such as diphenhydramine and
hydroxyzine) are preferable given their sedative properties.
Antiepilepticagents,suchaspregabalinandgabapentin,are
reported to provide pruritic relief in the general patient
population. It was suggested that pregabalin is capable of
relieving pruritus centrally and peripherally by reducing the
release of calcitonin gene-related peptide, which is a mediator
of itching in the periphery, as well as modification of central
perception of itch by a modulation of μ-opioid receptors
centrally [42]. The efficacy of gabapentin to reduce pruritus
associated with burns or with renal failure was reported in
trials of gabapentin alone or with various antihistamines [43,
44]. However, data in the setting of EGFRI-associated
pruritus is based on small case series [42]. In summary, these
antiepileptic agents should only be recommended as second-
line treatment in patients who failed antihistamines and
therapies against underlying rash and/or xerosis and continue
to experience clinically significant pruritus. Recently, aprepi-
tant, an NK-1 antagonist was reported to reduce pruritus that
is caused by erlotinib [38]. However, caution must be taken
as aprepitant may cause drug–drug interactions and poten-
tially affect the concentrations of erlotinib [45].
A number of over-the-counter topical agents are avail-
able for pruritus reduction. Menthol, a naturally occurring
Table 6 Pruritus recommendations
Recommend Not
recommended
Level of
evidence
Recommendation
grades
Comments
Preventive
Topical Gentle skin care instructions IV
a, b D Consensus of experts
Systemic Steroids IV
a, b D Consensus of experts
Treatment
Topical Menthol 0.5%–pramoxine 1%–doxepin III
b B Treat underlying condition
first (rash, xerosis) Medium- to high-potency steroids
(triamcinolone acetonide 0.025%; desonide
0.05%; fluticasone proprionate 0.05%;
alclometasone 0.05%)
Topical Antihistamines II
b C These agents can become
allergens, and can be
absorbed systemically
Lidocaine
Systemic Antihistamines
b I
c A Nonsedating first; some may
need adjustment for renal
impairment
Systemic Aprepitant
a V
a D
Systemic Gabapentin/pregabalin
a V
b/
a D Recommended as second-line
treatment only if
antihistamines fail
Systemic Doxepin V
a D
aEGFRI study
bNon-EGFRI noncancer treatment study
cNon-EGFRI cancer treatment study
1086 Support Care Cancer (2011) 19:1079–1095cyclic terpene alcohol of plant origin, is frequently used as an
antipruritic at concentrations of 1–3%. It has been shown that
menthol elicits the same cooling sensation as low temperature
through the TRPM8 receptor. Skin cooling has been demon-
stratedtoprovide therapeutic reliefinpatients whoexperience
pruritus. Menthol is a benign agent with minimal side effects
which can be used concurrently with systemic agents to
relieverashanditch[46]. Topical and oral doxepin have been
found to relieve pruritus in the general patient population
[47–49]. At this time, it is unknown whether other topical
agents, such as antihistamines, lidocaine, and calamine, will
provide adequate efficacy to alleviate pruritus induced by
EGFRIs. In the literature, topical antihistamines produce
mixed efficacy results, as reported in a recent review [50].
Furthermore, these agents are known to be sensitizers, which
may further induce secondary allergic contact dermatitis after
long-term usage of these agents [51]. Hence, we recommend
against routine usage of these agents to manage EGFRI-
induced pruritus.
Oral complications
Oral complications reported in EGFRI-treated patients are
infrequent. The most commonly reported oral complication
is mucositis. Oral mucositis may present with broad areas
of erythema, aphthous-like stomatitis, or superimposed
upon those of radiation and conventional chemotherapy
[52] (Fig. 1f, g). Severe mucositis is uncommon with
single-agent therapy; however, in combination with other
cytotoxic chemotherapy or radiation, severe and prolonged
mucositis may be seen. The pathobiology of EGFRI-
associated mucositis has yet to be elucidated. Other oral
side effects including taste change and salivary changes
have not been specifically reported. Sporadic patient self-
reporting indicates that other oral complications may be
underreported [53–61]. EGFRIs are commonly used in
combination with either chemotherapy or radiation therapy
(in the head and neck patient population). EGFRI-associated
mucositis may occur independent of or additive to oral
complications associated with radiation therapy and conven-
tional cytotoxic chemotherapy.
There are no trials investigating the management of
EGFRI-associated mucositis, thus guidance for prevention
and treatment was informed by current approaches to the
management of cytotoxic chemotherapy and radiation
therapy-induced mucositis as described in the MASCC
guidelines [62, 63]. Table 7 displays the recommendations
for the prevention and treatment of oral complications. The
approach recommended includes the foundation of (1)
thorough oral care, (2) aggressive pain management, (3)
adequate nutritional support, (4) radiation treatment plan-
ning that optimizes therapeutic index, and (5) benzydamine
rinse (not available in the USA) for radiation mucositis.
Oral health should be assessed prior to treatment and a
plan of care developed and implemented for individual
patients. Oral health status and oral care should be
evaluated periodically during treatment as well as after the
completion of therapy. Mucositis-associated pain should be
aggressively managed with topical analgesics and systemic
analgesics as needed. As mucosal pain has both nociceptive
and neuropathic components, opioids and adjuvant medi-
cations should be considered [64]. Nutrient and calorie
support of patients during and following cancer therapy is
strongly supported.
Many preventive and treatment strategies have been
investigated for oral mucositis; unfortunately, few have
been found to be efficacious (see the MASCC guidelines
for specific agents that have failed to demonstrate efficacy).
Diagnosis of contributing oral infections such as candidi-
asis, herpes virus reactivation, and mucositis allow for
specific intervention. Other approaches to EGFRI dermato-
logic toxicities are reported in this paper and some may
have application for the management of oral mucositis. For
example, minocycline and doxycycline have been studied
for the management of oral aphthous lesions [65, 66] and
the study of their potential application in the management
of mucositis associated with targeted therapies may be
indicated. Dermatitis is also managed with steroids, and
while use of steroids increases risk of secondary oral
infection (e.g., candidiasis), this may be managed with
currently available azole antifungals, although further study
is needed.
Xerosis and fissures
Abnormal keratinocyte differentiation due to EGFRIs leads to
a deteriorated stratum corneum with a decrease in loricrin,
which is the main protein holding together the scaffolding of
the epidermis [67, 68]. This process results in an unwoven
epidermal layer that cannot preserve moisture, thus resulting
in xerosis. Xerosis often is referred to as dry skin or
cutaneous dryness, which can turn into xerotic dermatitis
(asteatotic eczema), an inflammation resulting from dry skin.
It generally has a later onset, around 30–60 days or more into
EGFRI treatment, and often accompanies or succeeds the
papulopustular (acneiform) rash [22, 68]. Age, preexisting
eczema, and prior treatment with cytotoxics pose a greater
risk of xerosis [36, 67, 69].
To date, there are no existing randomized clinical trials
assessing the prevention or treatment of EGFRI-induced
xerosis. Table 8 displays the recommendations for the
prevention and treatment of xerosis. Preventive strategies
start with bathing techniques. Avoiding bathing in excess
and using tepid water as opposed to hot water is
recommended. When bathing, patients should be advised
to use bath oils or mild moisturizing soaps that are free of
Support Care Cancer (2011) 19:1079–1095 1087fragrances or perfumes. Avoiding extreme temperatures, such
as severe cold, dry weather or significant heat, and direct
sun exposure, which can cause sunburns, is also recommen-
ded [70]. Patients should refrain from using alcohol-
containing lotions or skin products that may dehydrate skin
[36, 38, 71].
Treatment of mild or moderate xerosis consists of thick
moisturizing creams without fragrances or potential irritants.
Moisturizers should be occlusive, emollient creams that are
generallypackagedinajarortubratherthanalotionthatcanbe
pumped or poured. Specific creams can include urea, colloidal
oatmeal, and petroleum-based creams. For scaly areas of
xerosis,ammonium lactateor lactic acidcreamscanbeutilized.
Greasy creams may be used on the limbs for better control of
xerosis but are cautioned on the face and chest, along with
extremely hairy sites, due to risk for folliculitis secondary to
occlusion [36, 38]. For more severe xerosis causing inflam-
mation with or without eczema, topical steroid creams may be
necessary. Topical retinoids and benzoyl peroxide gels are not
recommended due to their drying effect [38, 70, 72].
Skin fissures and deep cracks in the skin can form due to
significant xerosis (Fig. 1h). Fissures and skin cracking are
termed rhagades in the European literature [73]. They often
occur in the fingertips, in the palms or knuckles, and in the
Table 7 Oral complications recommendations
Recommend Not recommended Level of
evidence
Recommendation
grades
Comments
Preventive
Topical Benzydamine
(not FDA approved)
Antimicrobials
(chlorhexidine, lozenges)
II
a B Studied in radiation therapy
alone; not available
in USA
Topical Steroids III
b B For EGFRI dermatitis;
consensus of experts
Topical Cryotherapy (ice chips) I
a A For short half-life bolus
chemotherapy
Topical Low-level laser therapy II
a B Suggested; more
studies needed
Topical Azelastine, chamomile, coating
agents, traumeel, tretinoin
cream
III
a C Insufficient evidence
for guideline
Systemic Patient-controlled
analgesia for oral
mucositis pain
Antimicrobials (antiviral,
antifungal, antibacterial)
II
a B Consensus of experts
Systemic Palifermin (Kepivance) I
a A Recommended for
autologous HCT only
Systemic Pentoxifylline II
a B Not recommended in HCT
Miscellaneous Radiation blocks, IMRT IV
a D Consensus of opinion with
radiation therapy
Treatment
Topical Coating agents II
a B Insufficient evidence for
guidelines; consensus
of experts
Antimicrobials (chlorhexidine)
Topical Steroids III
a D Insufficient evidence for
guidelines; consensus of
experts
Traumeel
Tretinoin
Nonsteroidals
Prostaglandin
Topical Hematopoietic growth factors
(GCSF, GMCSF)
III
a B Not recommended
Systemic Antibiotics (radiation and
EGFRI dermatitis)
Pentoxifylline II
b/II
a B Consensus of experts
Doxycycline
aNon-EGFRI cancer treatment study
bEGFRI study
1088 Support Care Cancer (2011) 19:1079–1095soles—like xerosis, they are a late side effect of EGFRI
therapy, occurring around 30–60 days into therapy [19, 36].
They can be very painful and create risk for infection. As
with xerosis, there is no randomized clinical trial data
supporting prevention or treatment guidelines for EGFRI-
induced fissures. All recommendations are based on case
studies, observation, and expert opinion, as well as
dermatologic studies from the noncancer population.
Table 9 displays the recommendations for the prevention
and treatment of fissures. Wearing protective footwear or
covering the fingertips to avoid friction can prevent skin
fissures and aid healing. Treatment for skin fissures varies,
with many recommendations. Thick moisturizers or zinc
oxide creams can be applied. Bleach soaks can prevent
infection, with a dilution rate of one quarter cup of bleach to
3g a lo fw a t e r[ 34]. Liquid glues like cyanoacrylate
preparations (Superglue® or Liquid Bandaid®) can be used
to seal the cracks and keep them from worsening or
becoming infected [21, 34, 68, 74]. Sealing the cracks with
these products can also help relieve pain and allow for
healing [21, 74]. Propylene glycol 50% solution and salicylic
acid 10% ointment are other recommendations [1, 34, 67,
75]. Steroid tape (Cordran tape®) and hydrocolloid dressings
are recommended for painful, erythematous areas [34, 68,
73]. Limited evidence also supports the use of silver nitrate
or potassium permanganate foams and topical antibiotics
[38]. Oral antibiotics may be necessary if infection worsens
despite topical treatment.
Paronychia
All patients receiving EGFRIs are at risk for developing
nail changes, which typically develop after two or more
months of chemotherapy exposure [22, 76–80]. The most
commonly seen nail changes include nail fold inflammation
(paronychia) and periungual pyogenic granuloma-like
lesions (Fig. 1i). Resultant onycholysis or onychodystrophy
may result as a secondary process from the presence of nail
matrix inflammation.
Paronychia is characterized by tender, edematous, often
purulent inflammation of the nail folds. Fingernails and
toenails may be affected, with the first digits most
commonly affected. Precedent trauma is not believed to
be causative but rather an aggravating factor. Morbidity is
high, leading to significant pain, functional limitation, and
impairment of activities of daily living. Periungual pyo-
genic granulomata are characterized by friable vascular
tissue overgrowths on lateral nail folds. Easy bleeding is a
Table 8 Xerosis recommendations
Recommend Not
recommended
Level of
evidence
Recommendation
grades
Comments
Preventive
Topical Bathing techniques using bath oils
or mild moisturizing soaps and
bathing in tepid water
III B
Regular moisturizing creams
Other Avoid extreme temperatures
and direct sunlight
III
a B
Treatment
Topical
(mild/
moderate)
Emollient creams that are packaged
in a jar/tub that lack fragrances or
potential irritants
Alcohol-
containing
lotions
III B More greasy creams for use
on the limbs, but caution
use of greasy creams on the
face and chest
Occlusive emollients containing urea,
colloidal oatmeal, and petroleum-based
creams
Retinoids or
benzoyl
peroxide
Exfoliants may sting or burn
when applied to eroded or
erythematous skin—apply
only on intact skin For scaly areas, use exfoliants: ammonium
lactate 12% or lactic acid cream 12%
Urea creams (10–40%)
Salicylic acid 6%
Zinc oxide (13–40%)
Topical
(severe)
Medium- to high-potency steroid creams
(triamcinolone acetonide 0.025%; deso-
nide 0.05%; fluticasone proprionate
0.05%; alclometasone 0.05%)
III B
aEGFRI study
Support Care Cancer (2011) 19:1079–1095 1089common complaint. Increased local trauma is believed to be
an aggravating factor in inciting lesion development. The
mechanism for these vascular overgrowths is unclear, but it
is hypothesized to be related to EGFRI interruption of
retinoic acid metabolism [81].
TherearenoapprovedtreatmentsforEGFRI-associatednail
changes. Similarly, there have been no randomized controlled
studies evaluating therapies for paronychia. Recommendations
are based on expert opinionand anecdotal reports and Table 10
displays the recommendations for the prevention and treat-
ment of paronychia. Much of our knowledge comes from
prior experience with drug-induced paronychia and periun-
gual pyogenic granulomata, most notably from high-dose
systemic retinoid therapy and indinavir (human immunodefi-
ciency virus protease inhibitor) [82, 83].
Paronychia is a sterile process, but it has the potential to
become superinfected. Culturing of lesional skin to determine
ifsuperinfectionispresentisuniversallyrecommendedsothat
antimicrobials can be directed accordingly [84]. A retrospec-
tive study of 152 patients treated with cetuximab revealed 27
instances of paronychia (incidence of 17.7%). A total of 42
culture swabs were performed in which all grew some
organisms. The rate of coagulase-negative gram-positive
bacteria (nosocomial colonization) was 31%, which was
higher than the rate of S. aureus infection (23%) [85].
Managementstrategiesareaimedatminimizingperiungual
trauma, decreasing periungual inflammation, preventing
superinfection, and eliminating excessive granulation tissue.
Wearing comfortable shoes, trimming nails but avoiding
aggressive manicuring, and wearing gloves while cleaning
(e.g., household, dishes) are recommended to minimize
periungual trauma. Biotin has been found effective for the
treatment of brittle nails in the general population [86].
Topical corticosteroid and anti-inflammatory dose tetracy-
cline to decrease periungual inflammation and antimicrobial
soaks (e.g., dilute bleach in water; dilute white vinegar in
water) to prevent superinfection are recommended [87–97].
Additionally, electrocautery, silver nitrate, and nail avulsion
also are recommended to eliminate excessive granulation
tissue [98, 99].
Correlation of rash and therapeutic response
One of the observations made by early clinical investigators
was the correlation between the development of rash and
response to EGFRI therapy [100]. Clearly, this was an
important observation because, if rash proved to be a clinical
marker for response, it would offer patients a motivating
factor to work through the rash associated with the first
2 months of therapy in order to establish drug efficacy.
There are several methodological issues that must be
noted when interpreting the data addressing this question.
First, for most of the reported studies, the primary outcome
parameter was either response to therapy or overall
survival. Reporting of toxicities was a secondary aim; thus,
data collection has been largely passive by spontaneous
report. Passive data collection is believed to lead to
underreporting [101]. In addition, most clinical researchers
are not well versed in the assessment of dermatologic
toxicity. Finally, most clinical trials use toxicity assessment
scoring systems that are rather blunt outcome measures.
Although mixed, the bulk of data would tend to support
the correlation between rash and outcomes in patients
treated with EGFRI therapy. Positive correlations between
rash and outcome have been reported in studies using
cetuximab [102, 103], erlotinib [104, 105], gefitinib [106,
107], and panitumumab [108]. Data support not only an
increase in response but an increase in survival for those
patients experiencing a rash [102–107]. Although less
robust, there is also data to support that increasing severity
Table 9 Fissure recommendations
Recommend Not
recommended
Level of
evidence
Recommendation
grades
Comments
Preventive
Topical Wear protective footwear and avoid friction with
fingertips, toes, and heals
III B
Treatment
Topical Thick moisturizers or zinc oxide (13–40%) creams III
a/
b B Cream application often
impractical Liquid glues or cyanoacrylate to seal cracks
Steroids or steroid tape, hydrocolloid
dressings, topical antibiotics
Bleach soaks to prevent infection
Zinc oxide
aEGFRI study
bNon-EGFRI cancer treatment study
1090 Support Care Cancer (2011) 19:1079–1095of rash is correlated with increasing response and survival
[109]. These correlations appear across tumor types
including head and neck [104, 107], lung [105, 106], and
colorectal cancer [102, 103]. Conversely, there have been a
small number of studies that fail to correlate rash response
with outcome. In a 1,037 patient trial comparing paclitaxel
and carboplatin to paclitaxel, carboplatin, and gefitinib, no
correlation between rash and survival was seen. It should be
noted that this was a negative trial and that gefitinib failed
to improve outcome, thus obviating the potential predictive
benefit of rash [110].
Summary and discussion
Specific recommendations for preventative and reactive
interventions for EGFRI-associated dermatologic toxicities
are proposed herein. Patients should be educated about
these potential dermatological events before receiving
EGFRIs and, where possible, be encouraged to use
preventive measures. Regardless of strategy, patient educa-
tion prior to EGFRI therapy is critical in order to ensure
anticipatory coping, in which expectancy and preparation
for dermatologic changes allows patients not only to cope
but also to overcome the significant decrement to HQOL
posed by the toxicity (see Patient Education Brochure in the
Electronic supplementary material).
In addition to specific recommendations, we propose
that multidisciplinary teams including radiation oncolo-
gists, nurses, medical oncologists, dermatologists, phar-
macists, oral health care provider, and wound care
specialists should assess the occurrence and management
of EGRFI-associated dermatologic toxicities. Universal
recommendations for certain toxicities are not possible;
therefore, it is vital that the treatment team seek input
from wound care specialists, oral health care providers,
and dermatologists for specific and severe toxicities.
Furthermore, oncologists need to know how to address
commonly seen issues and to establish a referral pattern
with a dermatologist or oral health care provider with an
oncology area of focus.
Recommendations were based on randomized clinical
trials with control groups when possible; but, as mentioned
previously, the lack of quality studies investigating EGFRI-
associated dermatologic toxicities necessitates that many
recommendations be based on expert opinion and consensus.
FormostoftheEGFRI-associateddermatologictoxicities,itis
unlikelythatlargerandomizedclinicaltrialswillbeconducted
toinvestigatemanagementoptions.Thatbeingsaid,important
information may be garnered from treatment trials utilizing
EGFRIs either alone or in combination. We would, therefore,
recommend that dermatologic toxicities be documented in a
consistent and thorough manner in all future studies of
EGFRIs.
Table 10 Paronychia recommendations
Recommend Not recommended Level of
evidence
Recommendation
grades
Comments
Preventive
Topical Diluted bleach soaks II
a A Recommend final concentration
of approximately 0.005%
(approximately 1/4–1/8 cup
of 6% bleach for 3–5 gal water)
Avoid irritants
Treatment
Topical Corticosteroids Antifungals II
a A Recommend usage of ultrapotent
topical steroids as first-line therapy
given cost and availability of these
agents
Calcineurin inhibitors Antibiotics
Systemic Tetracyclines Empiric antibiotics—
employed without culturing
lesional skin
IV
b/II
a D/A
Antimicrobials: reserved
for culture proven
infection
Antifungals
Systemic Biotin for brittle nails III
a B
Other Silver nitrate chemical
cauterization weekly
IV
a D Reserved for pyogenic granulomata;
cnsensus of experts
Electrodessication
Nail avulsion
aNon-EGFRI noncancer treatment study
bEGFRI study
Support Care Cancer (2011) 19:1079–1095 1091One of the problems hindering the effective reporting and
management of EGFRI-associated dermatologic toxicities is
the use of varied, inconsistent toxicity criteria. To this end, the
Skin Toxicity Group proposed the use of the MASCC EGFRI
Skin Toxicity Tool (MESTT) [111] in clinical trials and in
clinical practice [for the website to download the MESTT,
see 112]. Although clinical trials often use the Common
Terminology Criteria for Adverse Events (NCICTCAE)
version 4.03 [113], this tool was not designed for reporting
EGFRI-associated dermatological events. The MESTT is a
more precise tool that can address the current state of
underreporting and inadequate assessment of these dermato-
logic adverse events. In fact, a recent study has demonstrated
that, while the grades of MESTT and CTCAE are well
correlated, the CTCAE tends to underreport the severity of
some of the dermatologic side events which can lead to the
under adjustment/discontinuation of treatment [114]. How-
ever, even with the use of standardized criteria, grading of
reactions remains somewhat subjective and this may impede
the comparison of toxicity findings between clinical studies.
An additional way to minimize discrepancy is to document
dermatologic toxicity photographically, thus enabling subse-
quent independent confirmation of grading where necessary.
It is recommended that digital photographic documentation
be adopted as a standard practice in clinical trials.
In summary, the mechanism of dermatologic toxicities
attributed to targeted therapies requires the assessment of
mechanistically directed interventions for prevention and
management. A greater understanding of the biological
mechanisms responsible for the toxicity of the individual
agents would lead to the development of rational and more
effective management strategies for the dermatologic
reactions of patients receiving radiotherapy and EGFRIs.
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